Tawee Tanvetyanon

8PUBLICATIONS
29CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsAutoimmunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 13, 2026
HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative Disease.

|Dec 10, 2025
Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis.

Tawee Tanvetyanon, Dung-Tsa Chen, Jhanelle E Gray

|Jun 05, 2025
Timeliness of Newer Targeted Therapy and Survival in Lung Cancer: A Population-Based Analysis.

Tawee Tanvetyanon, Utsav Joshi, Dung-Tsa Chen

|Oct 08, 2024
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

Xiuning Le, Jyoti D Patel, Elaine Shum

|Sep 28, 2024
Association between Infection and Calculated Globulin Level among Patients with Thymic Epithelial Tumor.

Joyce Cui, Tawee Tanvetyanon

|Apr 19, 2023
Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer.

Avani M Singh, Rafael Rubiera-Pebe, Yaser Ahmad

Pageof 2

Frequent Collaborators

2 joint publications

Dung-Tsa Chen

1 joint publications

Amber Skinner

1 joint publications

Damon R Reed

1 joint publications

Avani M Singh